(August 21, 2017) The US Food and Drug Administration (FDA) has granted full approval to olaparib tablets (Lynparza, AstraZeneca) for use as maintenance therapy for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who have achieved a complete or partial response to platinum-based chemotherapy.
This is not only a new indication for olaparib but also introduces a new formulation of the drug.
More information is available in this article from Medscape, and from the AstraZeneca press release.
